Fierce Biotech February 1, 2024
As clinical trials of its brain-computer interface progress, Synchron is laying the groundwork for the technology’s eventual commercial rollout.
That includes, most recently, taking on an equity stake in Acquandas, a German maker of tiny, high-tech components for medical devicemakers, among other clients.
Synchron announced the transaction in a Thursday release, in which founder and CEO Tom Oxley, M.D., Ph.D., noted, “As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces.”
Alongside its investment in Acquandas, Synchron will also send representatives to the company’s board, with Oxley joining its governance council and Riki Banerjee, Ph.D., Synchron’s newly appointed chief technology officer, becoming a board observer.
Acquandas’...
Today's Sponsors
Today's Sponsor